P3-097: Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non–squamous NSCLC
نویسندگان
چکیده
منابع مشابه
assessment of the effect of honey as a topical therapy for intra oral wound healing in rat.
چکیده ندارد.
15 صفحه اولNeoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
INTRODUCTION Sinonasal tumors are chemotherapy responsive which frequently present in advanced stages making NACT a promising option for improving resection and local control in borderline resectable and locally advanced tumours. Here we reviewed the results of 25 such cases treated with NACT. MATERIALS AND METHODS Sinonasal tumor patients treated with NACT were selected for this analysis. Th...
متن کاملWITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer.
BACKGROUND Gastric cancer is a major cause of cancer death, and many patients are only diagnosed when the cancer has reached an advanced stage. Neoadjuvant chemotherapy (NAC), that is, chemotherapy administered shortly before surgical treatment, could provide a method of increasing the possibility of complete resection and survival. OBJECTIVES To evaluate the effect of neoadjuvant chemotherap...
متن کاملPreparation and evaluation of 67Ga-DOTA-Bombesin (7-14) as a tumor scintigraphic agent
Introduction: Bombesin is a 14-aminoacid peptide isolated from frog skin. The mammalian counterparts of the frog peptide are neuromedin B (NMB) and gastrin-releasing peptide (GRP). Bombesin (BBN) is a peptide showing high affinity for the gastrin releasing peptide receptor (GRPr). Prostate, small cell lung cancer, breast, gastric, and colon cancers are known to over...
متن کاملBevacizumab added to neoadjuvant chemotherapy for breast cancer.
BACKGROUND Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by doxorubicin plus cyclophosphamide, would increase the rates of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2007
ISSN: 1556-0864
DOI: 10.1097/01.jto.0000284073.27558.49